Clinical Trials
53 trialsNCT07579195 2026-05-14
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
Phase 1/2 Not yet recruiting
NCT06290687 2026-05-07
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT07414992 2026-05-01
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Not yet recruiting
NCT05581589 2026-04-27
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
Phase 2 Terminated
NCT04960709 2026-04-14
VOLGA
AstraZeneca
Phase 3 Active not recruiting
NCT03609216 2026-04-13
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT07332351 2026-03-13
TRIFECTA
University of Washington
Phase 2 Not yet recruiting
NCT03520491 2026-02-17
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT07008833 2026-02-12
REDEMPTED
Brazilian Clinical Research Institute
Phase NA Not yet recruiting
NCT06263153 2025-12-17
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06091124 2025-12-08
NEOBLAST
RenJi Hospital
Phase 2 Recruiting
NCT07257718 2025-12-02
FUTURE
IRCCS San Raffaele
Phase 2 Not yet recruiting
NCT05241340 2025-10-24
RAD-VACCINE
The Methodist Hospital Research Institute
Phase 2 Active not recruiting
NCT03978624 2025-10-15
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07202819 2025-10-02
"NAC-MRI"
Assiut University
Phase NA Recruiting
NCT04383743 2025-09-18
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Phase 2 Completed
NCT06184516 2025-09-15
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
University of Florida
Phase 2 Recruiting
NCT03924856 2025-08-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03924895 2025-08-28
KEYNOTE-905
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07043790 2025-07-30
Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma
Ain Shams University
Phase NA Completed
NCT02968732 2025-07-04
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
Fox Chase Cancer Center
Phase NA Active not recruiting
NCT05312671 2025-06-29
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06957561 2025-05-04
DIVON
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT05776758 2025-04-16
Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt
Regina Elena Cancer Institute
Phase 3 Active not recruiting
NCT06928220 2025-04-15
CIMMIS
Fundacio Puigvert
Phase NA Completed
NCT00938145 2025-04-11
3 Tesla MRI in Patients With Bladder Cancer
University of Cincinnati
Phase NA Active not recruiting
NCT03674424 2025-02-26
AURA
Jules Bordet Institute
Phase 2 Completed
NCT04289779 2024-12-04
ABATE
Hoosier Cancer Research Network
Phase 2 Active not recruiting
NCT06341400 2024-12-04
RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Zhujiang Hospital
Phase 1/2 Recruiting
NCT04209114 2024-06-27
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT04391790 2023-04-27
MOSAIC
Aarhus University Hospital
Phase NA Unknown
NCT03529890 2022-10-20
RACE IT
Technical University of Munich
Phase 2 Unknown
NCT00777491 2022-06-15
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02924480 2022-03-09
Lidocaine
CAMC Health System
Phase NA Completed
NCT04570176 2022-02-16
Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System
The Affiliated Hospital of Qingdao University
Phase NA Completed
NCT02767921 2021-11-24
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
University of Southern California
Phase 1 Terminated
NCT03977831 2021-01-26
Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer
Rigshospitalet, Denmark
Phase NA Completed
NCT02861196 2020-12-17
Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Completed
NCT04588168 2020-10-19
Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT02716896 2019-11-25
Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase NA Terminated
NCT02699853 2019-05-03
Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer
University of Southern California
Phase NA Terminated
NCT00055601 2018-06-15
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02845050 2018-02-13
JaNEO
Ligartis GmbH
Phase 1/2 Withdrawn
NCT03238664 2018-01-02
Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors
University of Southern California
Phase NA Withdrawn
NCT02944357 2017-11-17
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
Mayo Clinic
Phase NA Withdrawn
NCT01938573 2017-10-20
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
University of Washington
Phase 1/2 Completed
NCT00380029 2017-07-19
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00859339 2016-04-14
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
Hoosier Cancer Research Network
Phase 2 Terminated